Key Highlights

  • Haoxi Health Technology (NASDAQ:HAO) traded at USD 1.70, down 13.27%, in pre-market trading on Tuesday, October 27, 2026. No company-specific announcement dated on or just before that day accompanied the move.
  • The annual report on Form 20-F filed on Wednesday, September 30, 2026 for the year ended June 30, 2026 shows revenue of about USD 54.83 million, up 67.1%, and a net loss of about USD 9.54 million.
  • The company completed a 1-for-128 reverse share split effective Thursday, May 21, 2026 and a 1-for-20 split on Friday, August 14, 2026, and sold shares in two registered direct offerings in 2026.
  • Pre-market prices are thinly traded and can change before the open at 9:30 a.m. ET. The share count is very small after the splits, which can amplify price swings.

The Pre-Market Move and Its Catalyst

Haoxi Health Technology (NASDAQ:HAO), a China-based company that provides digital marketing and livestreaming services, traded at USD 1.70, down 13.27%, in a pre-market snapshot on Tuesday, October 27, 2026. No company-specific announcement dated on or just before that day accompanied the move, and the most recent release of the company is dated Wednesday, August 12, 2026. That release announced a 1-for-20 reverse share split, which reduced Class A ordinary shares from 11,904,632 to about 595,232. The decline appears consistent with thin liquidity and with the dilution pattern of recent months, which is an inference. The company also announced a framework with NOVA MEDIA on an artificial intelligence digital marketing system on Tuesday, July 14, 2026.

How the Financing History and Annual Results Frame the Move

Haoxi Health Technology (NASDAQ:HAO) sold shares in a registered direct offering announced on Monday, May 11, 2026, of USD 6.5 million at USD 0.25 per share, and in a second offering announced on Friday, July 10, 2026, of USD 4 million at USD 0.40 per share. Both prices pre-date the splits. The annual report on Form 20-F filed on Wednesday, September 30, 2026 for the year ended June 30, 2026 shows revenue of about USD 54.83 million, up 67.1%, and a net loss of about USD 9.54 million against net income of about USD 3.9 million a year earlier. Cash was about USD 11 million, against about USD 8.6 million. These figures are rounded, and the reporting currency is taken to be USD.

Risks and What to Watch

The bull reading for Haoxi Health Technology (NASDAQ:HAO) is that revenue grew 67.1% and that cash rose to about USD 11 million, which gives the company funding to pursue its artificial intelligence marketing agreements. The bear reading is that the company moved from profit to a loss of about USD 9.54 million and that its two splits in 2026 reflect repeated share price pressure. Three risks stand out: further dilution from direct offerings, renewed Nasdaq minimum bid price non-compliance, which applies below USD 1.00, and low liquidity because the float is very small. Investors should watch any new offering or placement, its next periodic report, progress on the NOVA MEDIA and Eaglepoint AI frameworks and the Federal Reserve decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that Haoxi Health Technology (NASDAQ:HAO) fell in pre-market trading without a dated company announcement, and the move appears consistent with thin liquidity and a record of dilution and share consolidation. The key number is USD 1.70, a decline of 13.27% in the pre-market snapshot. The next catalysts are any new financing, progress on its artificial intelligence marketing frameworks, and the Federal Reserve decision on Wednesday, October 28, 2026, which follows the rate rise to 4.00% from 3.75% on Wednesday, September 16, 2026. Pre-market prices are snapshots and can change, and this is not investment advice.